R. McClatchey

R. McClatchey

The volumes and complexity of data that companies need to handle are increasing at an accelerating rate. In order to compete effectively and ensure their commercial sustainability, it is becoming crucial for them to achieve robust traceability in both their data and the evolving designs of their systems. This is addressed by the CRISTAL software which was originally developed at CERN by UWE, Bristol, for one of the particle detectors at the Large Hadron Collider, and has been subsequently transferred into the commercial world. Companies have been able to demonstrate increased agility, generate additional revenue, and improve the efficiency and cost-effectiveness with which they develop and implement systems in various areas, including business process management (BPM), healthcare and accounting applications. CRISTALs ability to manage data and its provenance at the terabyte scale, with full traceability over extended timescales, together with its description-driven approach, has provided the flexible adaptability required to future proof dynamically evolving software for these businesses.

R. McClatchey, A. Branson, A. Anjum et al.

With the increasingly digital nature of biomedical data and as the complexity of analyses in medical research increases, the need for accurate information capture, traceability and accessibility has become crucial to medical researchers in the pursuance of their research goals. Grid- or Cloud-based technologies, often based on so-called Service Oriented Architectures (SOA), are increasingly being seen as viable solutions for managing distributed data and algorithms in the bio-medical domain. For neuroscientific analyses, especially those centred on complex image analysis, traceability of processes and datasets is essential but up to now this has not been captured in a manner that facilitates collaborative study. Over the past decade, we have been working with mammographers, paediatricians and neuroscientists in three generations of projects to provide the data management and provenance services now required for 21st century medical research. This paper outlines the finding of a requirements study and a resulting system architecture for the production of services to support neuroscientific studies of biomarkers for Alzheimers Disease. The paper proposes a software infrastructure and services that provide the foundation for such support. It introduces the use of the CRISTAL software to provide provenance management as one of a number of services delivered on a SOA, deployed to manage neuroimaging projects that have been studying biomarkers for Alzheimers disease.